[go: up one dir, main page]

MX2023015534A - Peptidos y metodos para el tratamiento de la neuromielitis optica. - Google Patents

Peptidos y metodos para el tratamiento de la neuromielitis optica.

Info

Publication number
MX2023015534A
MX2023015534A MX2023015534A MX2023015534A MX2023015534A MX 2023015534 A MX2023015534 A MX 2023015534A MX 2023015534 A MX2023015534 A MX 2023015534A MX 2023015534 A MX2023015534 A MX 2023015534A MX 2023015534 A MX2023015534 A MX 2023015534A
Authority
MX
Mexico
Prior art keywords
treatment
peptides
methods
aqp4
cells
Prior art date
Application number
MX2023015534A
Other languages
English (en)
Inventor
Milos Erak
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of MX2023015534A publication Critical patent/MX2023015534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a péptidos inmunogénicos derivados de la acuaporina 4 (AQP4) para su uso en el tratamiento de los trastornos del espectro de la neuromielitis óptica (NMOSD) y a la generación de células T CD4+ citolíticas o células NKT contra células presentadoras de antígenos que presentan la secuencia epitópica de AQP4 de tipo silvestre.
MX2023015534A 2021-06-29 2022-06-29 Peptidos y metodos para el tratamiento de la neuromielitis optica. MX2023015534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21182499 2021-06-29
PCT/EP2022/067825 WO2023275108A1 (en) 2021-06-29 2022-06-29 Peptides and methods for the treatment of neuromyelitis optica

Publications (1)

Publication Number Publication Date
MX2023015534A true MX2023015534A (es) 2024-02-15

Family

ID=76999600

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015534A MX2023015534A (es) 2021-06-29 2022-06-29 Peptidos y metodos para el tratamiento de la neuromielitis optica.

Country Status (15)

Country Link
US (1) US20240228558A9 (es)
EP (1) EP4362972A1 (es)
JP (1) JP2024527274A (es)
KR (1) KR20240025673A (es)
CN (1) CN117729932A (es)
AR (1) AR126654A1 (es)
AU (1) AU2022304222A1 (es)
CA (1) CA3222570A1 (es)
CO (1) CO2024000603A2 (es)
CU (1) CU20230054A7 (es)
IL (1) IL309258A (es)
MX (1) MX2023015534A (es)
PE (1) PE20250119A1 (es)
TW (1) TW202306971A (es)
WO (1) WO2023275108A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202530251A (zh) * 2023-09-22 2025-08-01 德國符茲堡大學 ＭＨＣ Ｉｂ媒介之水通道蛋白４（ＡＱＰ４）特異性免疫抑制作為用於ＮＭＯ之新穎治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2476435T3 (pl) 2006-08-11 2018-05-30 Life Sciences Research Partners Vzw Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
AU2008350785B2 (en) * 2008-02-14 2013-10-03 Katholieke Universiteit Leuven Immunogenic peptides and their use in transplantation
WO2012069568A2 (en) 2010-11-25 2012-05-31 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
CA3019266A1 (en) 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
WO2018188730A1 (en) 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CN114746111A (zh) * 2019-11-27 2022-07-12 易姆赛斯股份公司 用于对糖尿病患者进行分层的方法
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations

Also Published As

Publication number Publication date
IL309258A (en) 2024-02-01
CN117729932A (zh) 2024-03-19
KR20240025673A (ko) 2024-02-27
AR126654A1 (es) 2023-11-01
CO2024000603A2 (es) 2024-05-10
WO2023275108A1 (en) 2023-01-05
CU20230054A7 (es) 2024-08-15
AU2022304222A1 (en) 2023-12-14
PE20250119A1 (es) 2025-01-16
US20240132556A1 (en) 2024-04-25
EP4362972A1 (en) 2024-05-08
TW202306971A (zh) 2023-02-16
AU2022304222A9 (en) 2024-01-11
US20240228558A9 (en) 2024-07-11
CA3222570A1 (en) 2023-01-05
JP2024527274A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2022013911A (es) Peptidos y metodos para el tratamiento de esclerosis multiple.
CL2018001845A1 (es) Moduladores de la 5'-nucleotidasa, ecto y su uso
MX2021000614A (es) Células diferenciadas de células pluripotentes inmunodiseñadas.
CL2023000426A1 (es) Neoantígenos ras y usos de los mismos
CO2024000603A2 (es) Péptidos y métodos para el tratamiento de neuromielitis óptica
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
MX2020004910A (es) Composiciones y métodos para el agotamiento de células cd5 +.
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CO2021007060A2 (es) Péptidos inmunogénicos con motivos de oxidorreductasa mejorados
CO2019009080A2 (es) Péptidos y métodos para el tratamiento de diabetes
BR112022017032A2 (pt) Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas.
BR112023002932A2 (pt) Vetores de adenovírus e métodos para uso de vetores de adenovírus
CL2021000532A1 (es) Vacunas peptídicas
CO2023018652A2 (es) Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
CO2022013978A2 (es) Terapia de aumento mitocondrial
UY40495A (es) 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1
CO2019012289A2 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar
CL2024000881A1 (es) Estructuras derivadas de tn3 específicas de cd40l para tratamiento y prevención del síndrome de sjogren
CL2024000580A1 (es) Vectores de hcmv recombinante y usos de estos
MX2021009662A (es) Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
CL2025002105A1 (es) Proteínas de fusión fc de il-12
CL2018003318A1 (es) Triazoles para la regulación de la homeostasis de calcio intracelular.
CL2024000600A1 (es) Vacunas contra la tuberculosis
AR115002A1 (es) Ehv con ul18 y/o ul8 inactivados